Clinical Trial Update: Safety and Biomarker Study of PTC-589 in Participants With Parkinson's Disease [Phase 2]

View source ↗

Summary

Phase 2 safety and biomarker study of PTC-589 in Parkinson's disease has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• PTC-589 (PTC-589)

Snippet

Sponsor: Edison Pharmaceuticals Inc | Conditions: Parkinson's Disease | Phase 2 | Status: COMPLETED | Results posted: 2022-05-03